



# Hepatitis C Re-Treatment Recommendations

If you have been treated for hepatitis C before, here are the recommendations for re-treatment for all genotypes from the [American Association for the Study of Liver Diseases \(AASLD\)](#) and [Infectious Diseases Society of America \(IDSA\)](#).

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Peginterferon and Ribavirin Treatment without Decompensated Cirrhosis or Certain Co-existing Medical Conditions, such as HCV Recurrence Post-Liver Transplant (Medications are listed first by evidence level according to the [HCVGuidelines.org](#), then listed alphabetically.)

|                                      | Recommended  | Alternative   |
|--------------------------------------|--|---|
| Genotype 1a<br>no cirrhosis          | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li><li>• Harvoni* for 12 weeks</li><li>• Mavyret for 8 weeks</li><li>• Zepatier for 12 weeks (without baseline NS5A RASs**)</li></ul> | <ul style="list-style-type: none"><li>• Daklinza + Sovaldi for 12 weeks</li><li>• Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**)</li></ul>         |
| Genotype 1a<br>compensated cirrhosis | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li><li>• Zepatier for 12 weeks (without baseline NS5A RASs**)</li><li>• Mavyret for 12 weeks</li></ul>                                | <ul style="list-style-type: none"><li>• Harvoni* + ribavirin for 12 weeks</li><li>• Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**)</li></ul>       |
| Genotype 1b<br>no cirrhosis          | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li><li>• Harvoni* for 12 weeks</li><li>• Mavyret for 8 weeks</li><li>• Zepatier for 12 weeks</li></ul>                                | <ul style="list-style-type: none"><li>• Daklinza + Sovaldi for 12 weeks</li></ul>   |
| Genotype 1b<br>compensated cirrhosis | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li><li>• Zepatier for 12 weeks</li><li>• Mavyret for 12 weeks</li></ul>   | <ul style="list-style-type: none"><li>• Harvoni* + ribavirin for 12 weeks</li></ul>   |
| Genotype 2<br>no cirrhosis           | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li><li>• Mavyret for 8 weeks</li></ul>  | <ul style="list-style-type: none"><li>• Daklinza + Sovaldi for 12 weeks</li></ul>   |
| Genotype 2<br>compensated cirrhosis  | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li><li>• Mavyret for 12 weeks</li></ul>   | <ul style="list-style-type: none"><li>• Daklinza + Sovaldi for 16 to 24 weeks</li></ul>   |
| Genotype 3<br>no cirrhosis           | <ul style="list-style-type: none"><li>• Epclusa* for 12 weeks</li></ul>  | <ul style="list-style-type: none"><li>• Daklinza + Sovaldi for 12 weeks</li><li>• Mavyret for 16 weeks</li><li>• Vosevi for 12 weeks (with Y93H RASs**)</li></ul> |

|                                     | Recommended   | Alternative  |
|-------------------------------------|---|--|
| Genotype 3<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Zepatier + Sovaldi for 12 weeks</li> <li>• Vosevi for 12 weeks</li> </ul>  | <ul style="list-style-type: none"> <li>• Epclusa* + ribavirin for 12 weeks</li> <li>• Mavyret for 16 weeks</li> </ul>  |
| Genotype 4<br>no cirrhosis          | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 8 weeks</li> <li>• Harvoni* for 12 weeks</li> <li>• Zepatier for 12 weeks for responder-relapsers to prior treatment</li> </ul> | <ul style="list-style-type: none"> <li>• Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV</li> </ul>  |
| Genotype 4<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> <li>• Zepatier for 12 weeks for responder-relapsers to prior treatment</li> </ul>                                 | <ul style="list-style-type: none"> <li>• Harvoni* + ribavirin for 12 weeks</li> <li>• Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV</li> </ul> |
| Genotype 5<br>no cirrhosis          | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> <li>• Mavyret for 8 weeks</li> </ul>   |  |
| Genotype 5<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Mavyret for 12 weeks</li> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> </ul>  |  |
| Genotype 6<br>no cirrhosis          | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> <li>• Mavyret for 8 weeks</li> </ul>   |  |
| Genotype 6<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Mavyret for 12 weeks</li> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> </ul>  |  |

### **Genotype 1a no cirrhosis**

|             |   |
|-------------|---|
| Recommended | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> <li>• Mavyret for 8 weeks</li> <li>• Zepatier for 12 weeks (without baseline NS5A RASs**)</li> </ul> |
| Alternative | <ul style="list-style-type: none"> <li>• Daklinza + Sovaldi for 12 weeks</li> <li>• Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**)</li> </ul>  |

### **Genotype 1a compensated cirrhosis**

|             |   |
|-------------|---|
| Recommended | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Zepatier for 12 weeks (without baseline NS5A RASs**)</li> <li>• Mavyret for 12 weeks</li> </ul> |
| Alternative | <ul style="list-style-type: none"> <li>• Harvoni* + ribavirin for 12 weeks</li> <li>• Zepatier + ribavirin for 16 weeks (with baseline NS5A RASs**)</li> </ul>            |

## **Genotype 1b no cirrhosis**

Recommended

- Epclusa\* for 12 weeks
- Harvoni\* for 12 weeks
- Mavyret for 8 weeks
- Zepatier for 12 weeks

Alternative

- Daklinza + Sovaldi for 12 weeks

## **Genotype 1b compensated cirrhosis**

Recommended

- Epclusa\* for 12 weeks
- Zepatier for 12 weeks
- Mavyret for 12 weeks

Alternative

- Harvoni\* + ribavirin for 12 weeks

## **Genotype 2 no cirrhosis**

Recommended

- Epclusa\* for 12 weeks
- Mavyret for 8 weeks

Alternative

- Daklinza + Sovaldi for 12 weeks

## **Genotype 2 compensated cirrhosis**

Recommended

- Epclusa\* for 12 weeks
- Mavyret for 12 weeks

Alternative

- Daklinza + Sovaldi for 16 to 24 weeks

## **Genotype 3 no cirrhosis**

Recommended

- Epclusa\* for 12 weeks
- Daklinza + Sovaldi for 12 weeks

Alternative

- Mavyret for 16 weeks
- Vosevi for 12 weeks (with Y93H RASs\*\*)

## **Genotype 3 compensated cirrhosis**

Recommended

- Zepatier + Sovaldi for 12 weeks
- Vosevi for 12 weeks

Alternative

- Epclusa\* + ribavirin for 12 weeks
- Mavyret for 16 weeks

## **Genotype 4 no cirrhosis**

Recommended

- Epclusa\* for 12 weeks
- Mavyret for 8 weeks
- Harvoni\* for 12 weeks
- Zepatier for 12 weeks for responder-relapsers to prior treatment

Alternative

- Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV

## **Genotype 4 compensated cirrhosis**

- Recommended
- Epclusa\* for 12 weeks
  - Mavyret for 12 weeks
  - Zepatier for 12 weeks for responder-relapsers to prior treatment
- Alternative
- Harvoni\* + ribavirin for 12 weeks
  - Zepatier + ribavirin for 16 weeks if prior treatment failed to suppress HCV

## **Genotype 5 no cirrhosis**

- Recommended
- Epclusa\* for 12 weeks
  - Harvoni\* for 12 weeks
  - Mavyret for 8 weeks
- Alternative

## **Genotype 5 compensated cirrhosis**

- Recommended
- Mavyret for 12 weeks
  - Epclusa\* for 12 weeks
  - Harvoni\* for 12 weeks
- Alternative

## **Genotype 6 no cirrhosis**

- Recommended
- Epclusa\* for 12 weeks
  - Harvoni\* for 12 weeks
  - Mavyret for 8 weeks
- Alternative

## **Genotype 6 compensated cirrhosis**

- Recommended
- Mavyret for 12 weeks
  - Epclusa\* for 12 weeks
  - Harvoni\* for 12 weeks
- Alternative

\*Generic version is available in the United States.

\*\*RASs = resistance-associated substitutions (formerly RAVs or resistance-associated variants)

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Treatment with Peginterferon, Ribavirin, and an HCV NS3 Protease Inhibitor (Incivek, Olysio, Victrelis)

(Medications are listed first by evidence level according to the [HCVGuidelines.org](https://www.hcvguidelines.org), then listed alphabetically.)

|                                     | Recommended  | Alternative   |
|-------------------------------------|--|---|
| Genotype 1<br>no cirrhosis          | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> | <ul style="list-style-type: none"> <li>• Zepatier + ribavirin for 12 weeks for genotype 1b and genotype 1a without baseline NS5A RASs**;<br/>16 weeks for genotype 1a with baseline NS5A RASs**</li> </ul>  |
| Genotype 1<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul>                                  | <ul style="list-style-type: none"> <li>• Harvoni* + ribavirin for 12 weeks</li> <li>• Zepatier + ribavirin for 12 weeks for genotype 1b and genotype 1a without baseline NS5A RASs**;<br/>16 weeks for genotype 1a with baseline NS5A RASs**</li> </ul> |

## Genotype 1 no cirrhosis

|             |  |
|-------------|--|
| Recommended | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Harvoni* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul>   |
| Alternative | <ul style="list-style-type: none"> <li>• Zepatier + ribavirin for 12 weeks for genotype 1b and genotype 1a without baseline NS5A RASs**;<br/>16 weeks for genotype 1a with baseline NS5A RASs**</li> </ul> |

## Genotype 1 compensated cirrhosis

|             |   |
|-------------|---|
| Recommended | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul>   |
| Alternative | <ul style="list-style-type: none"> <li>• Harvoni* + ribavirin for 12 weeks</li> <li>• Zepatier + ribavirin for 12 weeks for genotype 1b and genotype 1a without baseline NS5A RASs**;<br/>16 weeks for genotype 1a with baseline NS5A RASs**</li> </ul> |

\*Generic version is available in the United States.

\*\* RASs = resistance-associated substitutions (formerly RAVs or resistance-associated variants)

AASLDHCV Re-treatment Recommendations for People Who Failed Prior Non-NS5A Inhibitor Treatment Containing Sovaldi (Medications are listed first by evidence level according to the [HCVGuidelines.org](https://www.hcvguidelines.org), then listed alphabetically.)

|                                     | Recommended  | Alternative  |
|-------------------------------------|--|--|
| Genotype 1<br>no cirrhosis          | <ul style="list-style-type: none"> <li>• Vosevi for 12 weeks</li> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> | <ul style="list-style-type: none"> <li>• Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)</li> </ul> |
| Genotype 1<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Vosevi for 12 weeks</li> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> |  |
| Genotype 2<br>no cirrhosis          | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul>                                |  |
| Genotype 2<br>compensated cirrhosis | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul>                                |  |

|  | Recommended                       | Alternative |
|--|-----------------------------------|-------------|
| Genotype 3<br>no cirrhosis               | • Vosevi for 12 weeks             |             |
| Genotype 3<br>compensated cirrhosis      | • Vosevi + ribavirin for 12 weeks |             |
| Genotype 4<br>no cirrhosis               | • Vosevi for 12 weeks             |             |
| Genotype 4<br>compensated cirrhosis      | • Vosevi for 12 weeks             |             |
| Genotype 5 or 6<br>no cirrhosis          | • Vosevi for 8 weeks              |             |
| Genotype 5 or 6<br>compensated cirrhosis | • Vosevi for 12 weeks             |             |

### **Genotype 1 no cirrhosis**

|             |  |
|-------------|--|
| Recommended | <ul style="list-style-type: none"> <li>• Vosevi for 12 weeks</li> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> |
| Alternative | • Harvoni* + ribavirin for 12 weeks (except when previously failed Olysio treatment)   |

### **Genotype 1 compensated cirrhosis**

|             |  |
|-------------|--|
| Recommended | <ul style="list-style-type: none"> <li>• Vosevi for 12 weeks</li> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> |
| Alternative |  |

### **Genotype 2 no cirrhosis**

|             |   |
|-------------|---|
| Recommended | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> |
| Alternative |   |

### **Genotype 2 compensated cirrhosis**

|             |   |
|-------------|---|
| Recommended | <ul style="list-style-type: none"> <li>• Epclusa* for 12 weeks</li> <li>• Mavyret for 12 weeks</li> </ul> |
| Alternative |   |

### **Genotype 3 no cirrhosis**

|             |                       |
|-------------|-----------------------|
| Recommended | • Vosevi for 12 weeks |
| Alternative |                       |

**Genotype 3  
compensated cirrhosis**

Recommended

- Vosevi + ribavirin for 12 weeks

Alternative

**Genotype 4  
no cirrhosis**

Recommended

- Vosevi for 12 weeks

Alternative

**Genotype 4  
compensated cirrhosis**

Recommended

- Vosevi for 12 weeks

Alternative

**Genotype 5 or 6  
no cirrhosis**

Recommended

- Vosevi for 8 weeks

Alternative

**Genotype 5 or 6  
compensated cirrhosis**

Recommended

- Vosevi for 12 weeks

Alternative

\*Generic version is available in the United States.

AASLD HCV Re-treatment Recommendations for People Who Failed Prior Treatment with an NS5A Inhibitor Direct-Acting Antiviral (DAA) (Medications are listed first by evidence level according to the [HCVGuidelines.org](http://HCVGuidelines.org), then listed alphabetically.)

|  | Recommended   | Alternative   |
|--|---|---|
| Genotype 1<br>no cirrhosis or<br>compensated cirrhosis       | <ul style="list-style-type: none"><li>• Vosevi for 12 weeks</li></ul>   | <ul style="list-style-type: none"><li>• Mavyret for 16 weeks (except if previously treated with NS3/4 protease inhibitor DAA)</li></ul> |
| Genotype 3<br>no cirrhosis or<br>compensated cirrhosis       | <ul style="list-style-type: none"><li>• Vosevi for 12 weeks (+ ribavirin if cirrhosis and prior NS5A failure)</li></ul> |   |
| Genotype 4, 5, 6<br>no cirrhosis or<br>compensated cirrhosis | <ul style="list-style-type: none"><li>• Vosevi for 12 weeks</li></ul>   |   |

---

**Genotype 1  
no cirrhosis or  
compensated cirrhosis**

Recommended • Vosevi for 12 weeks

Alternative • Mavyret for 16 weeks (except if previously treated with NS3/4 protease inhibitor DAA)

**Genotype 3  
no cirrhosis or  
compensated cirrhosis**

Recommended • Vosevi for 12 weeks (+ ribavirin if cirrhosis and prior NS5A failure)

Alternative

**Genotype 4, 5, 6  
no cirrhosis or  
compensated cirrhosis**

Recommended • Vosevi for 12 weeks

Alternative

For those needing information about medication for advanced liver disease, visit [HCV treatment recommendations for those with decompensated cirrhosis](#). Click on [HCV Treatment Post-Transplantation](#) for information about HCV recurrence following liver transplantation.

Last Reviewed: March 11, 2019

---

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.hepmag.com/basics/hepatitis-c-basics/hepatitis-c-retreatment-recommendations>